隴神戎發(300534.SZ):1月10日起復牌 提示切勿盲目跟風炒作
格隆匯1月7日丨隴神戎發(300534.SZ)公佈,公司股票將於2022年1月10日開市起復牌。
公司2021年前三季度淨利潤為-818.68萬元,歸屬於上市公司股東的扣除非經常性損益的淨利潤為-1561.22萬元,公司前三季度為虧損。敬請投資者關注公司的公吿,謹慎投資。
根據中證指數有限公司官方網站發佈的證監會行業市盈率數據顯示,公司所處行業(C27醫藥製造業)近一個月平均市盈率為38.99,截至2021年12月30日收盤,公司最新滾動市盈率為697.24,遠高於同行業上市公司平均水平,公司股票價格短期內漲幅較大,特別提醒投資者注意二級市場交易風險,切勿盲目跟風炒作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.